![]() |
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C24H28N8O2 |
Molar mass | 460.542 g·mol−1 |
3D model ( JSmol) | |
| |
|
Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA). [1] [2]
Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study. [3] Currently running clinical trials [4] were continued for patients exhibiting benefit.
![]() |
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C24H28N8O2 |
Molar mass | 460.542 g·mol−1 |
3D model ( JSmol) | |
| |
|
Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA). [1] [2]
Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study. [3] Currently running clinical trials [4] were continued for patients exhibiting benefit.